Journal article
LBA 3 A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases
Authors
Clemons M; Stober C; Mates M; Joy AA; Robinson A; Hilton J; Blanchette P; Aseyev O; Pond G; Fergusson D
Journal
Annals of Oncology, Vol. 30, ,
Publisher
Elsevier
Publication Date
May 2019
DOI
10.1093/annonc/mdz118.002
ISSN
0923-7534